Cargando…
Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma: a meta-analysis
We sought to investigate safety of axitinib or sorafenib in renal cell carcinoma (RCC) patients and compare toxicity of these two vascular endothelial growth factor receptor inhibitors. Databases of PubMed and Embase were searched. We included phase II and III prospective trials, as well as retrospe...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Editorial Department of Journal of Biomedical Research
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956256/ https://www.ncbi.nlm.nih.gov/pubmed/29353818 http://dx.doi.org/10.7555/JBR.32.20170080 |